Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.

Pouzol L, Piali L, Bernard CC, Martinic MM, Steiner B, Clozel M.

Innov Clin Neurosci. 2019 Mar 1;16(3-4):22-30.

2.

High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.

Fuchs S, Sawas N, Staedler N, Schubert DA, D'Andrea A, Zeiser R, Piali L, Hruz P, Frei AP.

Eur J Immunol. 2019 Mar;49(3):462-475. doi: 10.1002/eji.201847862. Epub 2019 Jan 9.

PMID:
30578679
3.

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, Kohl C, Rey M, Studer R, Vezzali E, Hess P, Clozel M, Steiner B, Bolli MH, Nayler O.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.370.

4.

Expression of checkpoint molecules on myeloid-derived suppressor cells.

Ballbach M, Dannert A, Singh A, Siegmund DM, Handgretinger R, Piali L, Rieber N, Hartl D.

Immunol Lett. 2017 Dec;192:1-6. doi: 10.1016/j.imlet.2017.10.001. Epub 2017 Oct 4.

PMID:
28987474
5.

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.

You S, Piali L, Kuhn C, Steiner B, Sauvaget V, Valette F, Clozel M, Bach JF, Chatenoud L.

PLoS One. 2013 Oct 24;8(10):e77296. doi: 10.1371/journal.pone.0077296. eCollection 2013.

6.

G-protein coupled receptors: drug targets of key importance.

Piali L, Richardson DR.

Curr Top Med Chem. 2011;11(6):608. No abstract available.

PMID:
21418015
7.

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M.

J Pharmacol Exp Ther. 2011 May;337(2):547-56. doi: 10.1124/jpet.110.176487. Epub 2011 Feb 23.

PMID:
21345969
8.

The role of CCL21 in recruitment of T-precursor cells to fetal thymi.

Liu C, Ueno T, Kuse S, Saito F, Nitta T, Piali L, Nakano H, Kakiuchi T, Lipp M, Hollander GA, Takahama Y.

Blood. 2005 Jan 1;105(1):31-9. Epub 2004 Sep 9.

PMID:
15358618
9.

Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on gammadelta cells.

Ferrero E, Biswas P, Vettoretto K, Ferrarini M, Uguccioni M, Piali L, Leone BE, Moser B, Rugarli C, Pardi R.

Immunology. 2003 Mar;108(3):365-74.

10.

Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis.

Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Holländer GA, Piali L.

Nat Med. 2002 Dec;8(12):1414-20. Epub 2002 Nov 4.

PMID:
12415259
11.

Wnt glycoproteins regulate the expression of FoxN1, the gene defective in nude mice.

Balciunaite G, Keller MP, Balciunaite E, Piali L, Zuklys S, Mathieu YD, Gill J, Boyd R, Sussman DJ, Holländer GA.

Nat Immunol. 2002 Nov;3(11):1102-8. Epub 2002 Oct 15.

12.
13.

CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.

Maloy KJ, Burkhart C, Junt TM, Odermatt B, Oxenius A, Piali L, Zinkernagel RM, Hengartner H.

J Exp Med. 2000 Jun 19;191(12):2159-70.

14.

Chemokines and chemotaxis of leukocytes in infectious meningitis.

Lahrtz F, Piali L, Spanaus KS, Seebach J, Fontana A.

J Neuroimmunol. 1998 May 1;85(1):33-43. Review.

PMID:
9626995
15.

The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig.

Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B.

Eur J Immunol. 1998 Mar;28(3):961-72.

16.

Lymphocyte responses to chemokines.

Moser B, Loetscher M, Piali L, Loetscher P.

Int Rev Immunol. 1998;16(3-4):323-44. Review.

PMID:
9505194
17.

Cross talk between alpha(v)beta3 and alpha4beta1 integrins regulates lymphocyte migration on vascular cell adhesion molecule 1.

Imhof BA, Weerasinghe D, Brown EJ, Lindberg FP, Hammel P, Piali L, Dessing M, Gisler R.

Eur J Immunol. 1997 Dec;27(12):3242-52.

PMID:
9464812
18.
19.

To stick or not to stick: the new leukocyte homing paradigm.

Dunon D, Piali L, Imhof BA.

Curr Opin Cell Biol. 1996 Oct;8(5):714-23. Review.

PMID:
8939652
20.

Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.

Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B.

J Exp Med. 1996 Sep 1;184(3):963-9.

21.

Involvement of alpha 6 and alpha v integrins in metastasis.

Imhof BA, Piali L, Gisler RH, Dunon D.

Curr Top Microbiol Immunol. 1996;213 ( Pt 1):195-203. Review. No abstract available.

PMID:
8814987
22.

CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium.

Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, Imhof BA.

J Cell Biol. 1995 Jul;130(2):451-60.

23.

Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma.

Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH.

J Exp Med. 1995 Feb 1;181(2):811-6.

24.

Adhesion molecule PECAM-1/CD31 is expressed on defined subsets of murine LAK cells.

Piali L, Imhof BA, Gisler RH.

Adv Exp Med Biol. 1994;355:147-53. No abstract available.

PMID:
7709814
25.

Murine platelet endothelial cell adhesion molecule (PECAM-1)/CD31 modulates beta 2 integrins on lymphokine-activated killer cells.

Piali L, Albelda SM, Baldwin HS, Hammel P, Gisler RH, Imhof BA.

Eur J Immunol. 1993 Oct;23(10):2464-71.

PMID:
8405046

Supplemental Content

Support Center